Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP7 | P09237 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25880720 | 0.91 | MMP13 (0.38) | MMP13MMP1MMP2MMP3MMP7 | |
| SCHEMBL25878005 | 0.89 | MMP13 (0.40) | MMP13MMP1MMP2MMP3MMP7 | |
| SCHEMBL25877328 | 0.89 | MMP7 (0.42) | MMP13MMP1MMP2MMP3MMP7 | |
| SCHEMBL30787103 | 0.87 | CTSV (0.39) | MMP13 | |
| SCHEMBL25877986 | 0.86 | SLC1A3 (0.38) | — | |
| SCHEMBL25878425 | 0.86 | CTSV (0.31) | — | |
| SCHEMBL26270003 | 0.86 | ALDH1A1 (0.36) | MMP13MMP1MMP2MMP3MMP7 | |
| SCHEMBL25878684 | 0.84 | NR3C1 (0.35) | MMP13MMP1MMP2MMP9CA1 | |
| SCHEMBL25664730 | 0.84 | CTSV (0.33) | — | |
| SCHEMBL25878180 | 0.83 | ALDH1A1 (0.34) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234921-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234921-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | SERPINB1, CTSV, CTSE | MMP13 130/4885MMP1 127/4885MMP2 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.